A Galactose Dendritic Silicon (IV) Phthalocyanine as a Photosensitizing Agent in Cancer Photodynamic Therapy. Issue 9 (13th September 2018)

• Record Type: Journal Article
• Authors: Bispo, Mafalda; Pereira, Patrícia M. R.; Setaro, Francesca; Rodríguez‐Morgade, M. Salomé; Fernandes, Rosa; Torres, Tomás; Tomé, João P. C.
• Is Part Of: ChemPlusChem. Volume 83:Issue 9(2018)
• Page Start: 855
• Page End: 860
• Publication Date: 2018-09-13
• Subjects: Cancer -- dendrimers -- galactose -- photodynamic therapy -- phthalocyanines; Chemistry -- Periodicals; 540.5
• DOI: 10.1002/cplu.201800370
• Languages: English
• ISSNs: 2192-6506

Abstract

Abstract: Two protected galacto‐dendritic units have been axially coordinated to the central ion of a silicon(IV) phthalocyanine to affordSiPcPGal4 containing four units of galactose per macrocycle. These biological moieties provided better solubility in aqueous medium and a sensitizer with higher absorption peaks at 680–690 nm. The photodynamic activity ofSiPcPGal4 was evaluated against UM‐UC‐3 human bladder cancer cell line and the results were compared with the activity of the reportedSiPcPGal2 andSiPc(OH)2 .SiPcPGal4 had a better uptake and it was a better toxicity inducer thanSiPcPGal2 andSiPc(OH)2 owing to its four galactose units, protected by isopropylidene groups, which can act as targeted micelles. Abstract : Zapping cancer : Solketal‐protected galactose dendritic units were attached to the axial position of a silicon phthalocyanine and the resultingSiPcPGal4 dye was tested as a photosensitizer for photodynamic therapy in UM‐UC‐3 bladder cancer cells. The observed toxicity ofSiPcPGal4 upon light activation arises in part from its enhanced cellular uptake.